{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Number of participants with dose-limiting toxicities (DLTs). DLTs were collected and evaluated for Part A within the DLT evaluation period, which started on Cycle 1 Day 1 (first dose) and ended at Day 42 (42 days after first dose of the study therapy).","groups":[{"description":"Bempegaldesleukin 0.006 mg/kg + Nivolumab 4.5 mg/kg administered intravenously every 3 weeks","id":"OG000","title":"Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)"},{"description":"Bempegaldesleukin 0.006 mg/kg + Nivolumab 360 mg administered intravenously every 3 weeks","id":"OG001","title":"Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants in Part A","reportingStatus":"POSTED","timeFrame":"From first dose to 42 days after first dose","title":"Number of Participants With Dose-Limiting Toxicities (DLTs) - Part A","type":"PRIMARY","unitOfMeasure":"Participants"}